Navigation Links
Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results
Date:2/23/2009

First Full Year of Profitability with GAAP Earnings Per Share of $0.03

2008 Nexavar Net Sales of $678 Million Represents 82% Growth Over 2007

EMERYVILLE, Calif., Feb. 23 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today reported its financial results for the full year and fourth quarter 2008. For the full year, Onyx recorded net income of $1.9 million, or $0.03 per diluted share, compared with a net loss of $34.2 million, or $0.67 per diluted share, for the same period in 2007. Excluding employee stock-based compensation expense, non-GAAP net income for the full year 2008 was $20.7 million, or $0.37 per diluted share, compared to a non-GAAP net loss of $20.0 million, or $0.39 per diluted share, for the same period in 2007. Onyx reported a net loss of $30.2 million, or $0.53 per diluted share, for the fourth quarter 2008, compared to a net loss of $11.7 million, or $0.21 per diluted share, in the same period in 2007. Excluding employee stock-based compensation expense, non-GAAP net loss for the fourth quarter 2008 was $25.2 million, or $0.45 per diluted share, compared to a non-GAAP net loss of $7.8 million, or $0.14 per diluted share, for the same period in 2007. A description of the non-GAAP calculations and reconciliation to comparable GAAP measures are provided below in the accompanying Reconciliation of GAAP to Non-GAAP Net Income.

Global Nexavar net sales grew 82% to $677.8 million for the full year 2008, and grew 41% to $176.5 million for the fourth quarter 2008, compared to $371.7 million and $124.9 million in the same periods in 2007. Onyx, with its collaborator, Bayer HealthCare Pharmaceuticals, Inc., or Bayer, is marketing and developing Nexavar(R) (sorafenib) tablets, an anticancer therapy currently approved for the treatment of liver cancer and advanced kidney cancer in th
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ... 2015 , ... Healthcare IT News (HITN), the ... healthcare and technology markets, today announced significant spikes in website traffic and social ... Record (EHR) decision. The DOD related numbers solidify HITN’s status as the leading ...
(Date:8/3/2015)... ... , ... While the pace of the economic recovery since the 2008 has been subject to ... trajectory for the last six years. Unemployment has dropped from a 2009 high of 10 ... growth rate in 2014, the U.S. stock market is at an all time high, and ...
(Date:8/3/2015)... ... August 04, 2015 , ... The American Academy of ... new internationally peer-reviewed Guidelines were prepared by members of the AAT as a ... evaluating patients with dental-oral and systemic health-related complaints. , Thermography is a ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sutter Health’s California Pacific Medical center announces ... CPMC. Hamila will start in her role effective immediately and will have responsibility for ... at CPMC and Sutter Health for about 15 years, including the past 7 years ...
(Date:8/3/2015)... , ... August 03, 2015 , ... Since 1978, the ... declined, according to a new publication released today by the AAMC (Association of American ... college graduates over the past three decades, the number of black male applicants to ...
Breaking Medicine News(10 mins):Health News:Coverage of DOD’s EHR Decision Reinforces Healthcare IT News’ Leadership 2Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 2Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 3Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 4Health News:American Academy of Thermology (AAT) Publishes First-Ever Guidelines for Oral-Systemic Thermography 2Health News:American Academy of Thermology (AAT) Publishes First-Ever Guidelines for Oral-Systemic Thermography 3Health News:Hamila Kownacki, RN Appointed as New Chief Operating Officer at CPMC 2Health News:New Publication Focuses on the Decline of Black Males in Medicine 2Health News:New Publication Focuses on the Decline of Black Males in Medicine 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 4
... CLEMENS, Mich., Nov. 25 Two more H1N1 vaccine clinics have ... Macomb County Health Department announced today. They are being offered at ... in Sterling Heights. , The Dec. 3 clinic will be held ... from 9 a.m. to 3 p.m. The thimerosol-free version of the ...
... Fla., Nov. 25 Daniel Touizer, CEO of Ci n ... guaranteed issue health insurance benefit programs, is concerned that the labor department,s recently ... job and unlikely to have health insurance. , "True unemployment ... highest rate in over 20 years," says Dani e ...
... and Spanish . Researchers from the ... ocular diseases that are very common today, such as age-related macular ... had never before been used for this purpose. Scientists from ... affected by one of these two pathologies, finding a greater amount ...
... available in French . Montreal, November 25, ... marketplace, thanks to a new partnership between Gestion Univalor, ... privately owned technology company based in Montreal. Univalor, ... its affiliated institutions, and CSI have announced the signature ...
... Discovery in fruit fly study may lead to new drugs ... -- Sphingadienes, natural lipid molecules found in soy, could become ... have found. , The findings are preliminary, but the ... soy seems to provide protection against colon cancer. , In ...
... experts offer waistline-friendly ways to enjoy festive feasting , WEDNESDAY, ... holiday smorgasbord from Thanksgiving to New Year,s, but are already ... come Jan. 1, help is at hand. , It,s possible, ... make it to 2010 weighing the same as you do ...
Cached Medicine News:Health News:Macomb County Health Department Schedules Two More H1N1 Flu Vaccine Clinics Dec. 3 and 5 2Health News:Cinergy Health Commentary on Health Care for the Unemployed 2Health News:Achieve early diagnosis of ocular pathologies such as keratitis and macular degeneration 2Health News:Univalor and Cognitive Sensing Inc. to commercialize 4 University of Montreal discoveries 2Health News:Natural Soy Component May Help Treat Colon Cancer 2Health News:Holiday Eating Without the Guilt -- or the Pounds 2Health News:Holiday Eating Without the Guilt -- or the Pounds 3
(Date:8/3/2015)... 2015  Landauer, Inc. (NYSE: LDR ), a ... monitoring, outsourced medical physics services and high quality medical ... for the fiscal third quarter 2015 after the market ... The Company will also host a conference call for ... Central Time (10:00 a.m. Eastern Time). Investors may access ...
(Date:8/3/2015)... AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), ... commercialization of innovative therapies for the treatment of acute ... results for the three and six months ended June ... On July 23, 2015, the Committee for Medicinal Products ... Zalviso™ for the management of acute moderate-to-severe post-operative pain ...
(Date:8/3/2015)... -- LEO Pharma supports the recent decision by the U.S. ... one of eight priority disease areas in its 2016-2017 ... an autoimmune disease that has a major impact on ... in the US alone. ii As ... living with psoriasis, LEO Pharma along with the National ...
Breaking Medicine Technology:Landauer, Inc. Announces Date And Time For Announcement Of Fiscal Third Quarter 2015 Results And Conference Call 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 3AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 4AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 5AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 6AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 7AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 8AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 9AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 10LEO Pharma Supports the FDA's Selection of Psoriasis as a Priority Disease 2LEO Pharma Supports the FDA's Selection of Psoriasis as a Priority Disease 3
... events organiser UBM Live , a division of UBM ... CPhI Worldwide and collocated events will be hosted in Madrid, ... for contract and outsourced services and logistics, P-MEC for pharmaceutical ... line-up, InnoPack for pharmaceutical packaging needs. The events will run ...
... 2011 Reportlinker.com announces that a new ... catalogue: Specialty Pharmaceutical Industry ... http://www.reportlinker.com/p0512130/Specialty-Pharmaceutical-Industry---2011-Yearbook.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology Specialty Pharmaceutical Industry ... GBI Research,s "Specialty Pharmaceutical ...
Cached Medicine Technology:CPhI Worldwide, ICSE, P-MEC and InnoPack Announce 2012 Events Location 2CPhI Worldwide, ICSE, P-MEC and InnoPack Announce 2012 Events Location 3Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 2Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 3Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 4Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 5Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 6Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 7Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 8Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 9Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 10Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 11Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 12Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 13Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 14Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 15Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 16
... OraQuick is an FDA ... venipuncture whole blood test used ... of HIV-1 infection. This CLIA ... presence of antibodies to HIV-1, ...
... Mononucleosis test is designed to detect ... plasma or whole blood. The QuickVue+ ... of bovine erythrocytes which give a ... extracts prepared from sheep and horse ...
... available point-of-care diagnostic test that can reliably ... A and B. The test uses a ... that assists viral replication by promoting the ... The ZstatFlu substrate is labeled with a ...
The NOW Flu A test is the most frequently adopted rapid flu test on the market today. Testing could not be easier and the results are available in 15 minutes. Now you can focus on the results and tre...
Medicine Products: